1 Study Coverage 1.1 Primary Sclerosing Cholangitis Treatment Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Introduction 1.2 Global Primary Sclerosing Cholangitis Treatment Outlook 2017 VS 2022 VS 2028 1.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size for the Year 2017-2028 1.2.2 Global Primary Sclerosing Cholangitis Treatment Market Size for the Year 2017-2028 1.3 Primary Sclerosing Cholangitis Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Primary Sclerosing Cholangitis Treatment in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Primary Sclerosing Cholangitis Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Primary Sclerosing Cholangitis Treatment Market Dynamics 1.4.1 Primary Sclerosing Cholangitis Treatment Industry Trends 1.4.2 Primary Sclerosing Cholangitis Treatment Market Drivers 1.4.3 Primary Sclerosing Cholangitis Treatment Market Challenges 1.4.4 Primary Sclerosing Cholangitis Treatment Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Primary Sclerosing Cholangitis Treatment by Type 2.1 Primary Sclerosing Cholangitis Treatment Market Segment by Type 2.1.1 Liver Transplantation Operation 2.1.2 UDCA Drugs 2.1.3 PSC Drugs 2.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2017, 2022 & 2028) 2.3 Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2028) 2.4 United States Primary Sclerosing Cholangitis Treatment Market Size by Type (2017, 2022 & 2028) 2.5 United States Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2028) 3 Primary Sclerosing Cholangitis Treatment by Application 3.1 Primary Sclerosing Cholangitis Treatment Market Segment by Application 3.1.1 Hospital 3.1.2 Clinics 3.1.3 Other 3.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2017, 2022 & 2028) 3.3 Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2028) 3.4 United States Primary Sclerosing Cholangitis Treatment Market Size by Application (2017, 2022 & 2028) 3.5 United States Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2028) 4 Global Primary Sclerosing Cholangitis Treatment Competitor Landscape by Company 4.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Company 4.1.1 Top Global Primary Sclerosing Cholangitis Treatment Companies Ranked by Revenue (2021) 4.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue by Player (2017-2022) 4.2 Global Primary Sclerosing Cholangitis Treatment Concentration Ratio (CR) 4.2.1 Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Primary Sclerosing Cholangitis Treatment in 2021 4.2.3 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Primary Sclerosing Cholangitis Treatment Headquarters, Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Type 4.3.1 Global Primary Sclerosing Cholangitis Treatment Headquarters and Area Served 4.3.2 Global Primary Sclerosing Cholangitis Treatment Companies Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Primary Sclerosing Cholangitis Treatment Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Primary Sclerosing Cholangitis Treatment Market Size by Company 4.5.1 Top Primary Sclerosing Cholangitis Treatment Players in United States, Ranked by Revenue (2021) 4.5.2 United States Primary Sclerosing Cholangitis Treatment Revenue by Players (2020, 2021 & 2022) 5 Global Primary Sclerosing Cholangitis Treatment Market Size by Region 5.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2028) 5.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Region: 2017-2022 5.2.2 Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2017-2028 6.1.2 North America Primary Sclerosing Cholangitis Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2017-2028 6.3.2 Europe Primary Sclerosing Cholangitis Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2017-2028 6.4.2 Latin America Primary Sclerosing Cholangitis Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 Allergan 7.1.1 Allergan Company Details 7.1.2 Allergan Business Overview 7.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction 7.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.1.5 Allergan Recent Development 7.2 Glenmark 7.2.1 Glenmark Company Details 7.2.2 Glenmark Business Overview 7.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction 7.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.2.5 Glenmark Recent Development 7.3 Impax Laboratories 7.3.1 Impax Laboratories Company Details 7.3.2 Impax Laboratories Business Overview 7.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction 7.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.3.5 Impax Laboratories Recent Development 7.4 Mylan 7.4.1 Mylan Company Details 7.4.2 Mylan Business Overview 7.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction 7.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.4.5 Mylan Recent Development 7.5 Teva Pharmaceuticals 7.5.1 Teva Pharmaceuticals Company Details 7.5.2 Teva Pharmaceuticals Business Overview 7.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction 7.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.5.5 Teva Pharmaceuticals Recent Development 7.6 Dr. Falk Pharma 7.6.1 Dr. Falk Pharma Company Details 7.6.2 Dr. Falk Pharma Business Overview 7.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction 7.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.6.5 Dr. Falk Pharma Recent Development 7.7 Daewoong Pharmaceutical 7.7.1 Daewoong Pharmaceutical Company Details 7.7.2 Daewoong Pharmaceutical Business Overview 7.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction 7.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.7.5 Daewoong Pharmaceutical Recent Development 7.8 Epic Pharma 7.8.1 Epic Pharma Company Details 7.8.2 Epic Pharma Business Overview 7.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction 7.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.8.5 Epic Pharma Recent Development 7.9 Mitsubishi Tanabe Pharma 7.9.1 Mitsubishi Tanabe Pharma Company Details 7.9.2 Mitsubishi Tanabe Pharma Business Overview 7.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction 7.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.9.5 Mitsubishi Tanabe Pharma Recent Development 7.10 Lannett 7.10.1 Lannett Company Details 7.10.2 Lannett Business Overview 7.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction 7.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.10.5 Lannett Recent Development 7.11 Bruschettini 7.11.1 Bruschettini Company Details 7.11.2 Bruschettini Business Overview 7.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction 7.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.11.5 Bruschettini Recent Development 7.12 Shanghai Pharma 7.12.1 Shanghai Pharma Company Details 7.12.2 Shanghai Pharma Business Overview 7.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction 7.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.12.5 Shanghai Pharma Recent Development 7.13 Grindeks 7.13.1 Grindeks Company Details 7.13.2 Grindeks Business Overview 7.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction 7.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.13.5 Grindeks Recent Development 7.14 Acorda Therapeutics 7.14.1 Acorda Therapeutics Company Details 7.14.2 Acorda Therapeutics Business Overview 7.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction 7.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.14.5 Acorda Therapeutics Recent Development 7.15 Gilead Sciences 7.15.1 Gilead Sciences Company Details 7.15.2 Gilead Sciences Business Overview 7.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction 7.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.15.5 Gilead Sciences Recent Development 7.16 Intercept Pharmaceuticals 7.16.1 Intercept Pharmaceuticals Company Details 7.16.2 Intercept Pharmaceuticals Business Overview 7.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction 7.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.16.5 Intercept Pharmaceuticals Recent Development 7.17 Shire Plc 7.17.1 Shire Plc Company Details 7.17.2 Shire Plc Business Overview 7.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction 7.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.17.5 Shire Plc Recent Development 7.18 NGM Biopharmaceuticals 7.18.1 NGM Biopharmaceuticals Company Details 7.18.2 NGM Biopharmaceuticals Business Overview 7.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction 7.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.18.5 NGM Biopharmaceuticals Recent Development 7.19 Conatus Pharmaceuticals 7.19.1 Conatus Pharmaceuticals Company Details 7.19.2 Conatus Pharmaceuticals Business Overview 7.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction 7.19.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.19.5 Conatus Pharmaceuticals Recent Development 7.20 Durect Corporation 7.20.1 Durect Corporation Company Details 7.20.2 Durect Corporation Business Overview 7.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction 7.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.20.5 Durect Corporation Recent Development 7.21 Sirnaomics 7.21.1 Sirnaomics Company Details 7.21.2 Sirnaomics Business Overview 7.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction 7.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.21.5 Sirnaomics Recent Development 7.22 Shenzhen HighTide Biopharmaceuticals 7.22.1 Shenzhen HighTide Biopharmaceuticals Company Details 7.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview 7.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction 7.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) 7.22.5 Shenzhen HighTide Biopharmaceuticals Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Primary Sclerosing Cholangitis Treatment Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Primary Sclerosing Cholangitis Treatment Market Trends Table 3. Primary Sclerosing Cholangitis Treatment Market Drivers Table 4. Primary Sclerosing Cholangitis Treatment Market Challenges Table 5. Primary Sclerosing Cholangitis Treatment Market Restraints Table 6. Global Primary Sclerosing Cholangitis Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Primary Sclerosing Cholangitis Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Primary Sclerosing Cholangitis Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Primary Sclerosing Cholangitis Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Primary Sclerosing Cholangitis Treatment Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Primary Sclerosing Cholangitis Treatment Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Player, 2017-2022 Table 13. Global Primary Sclerosing Cholangitis Treatment Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Primary Sclerosing Cholangitis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2021) Table 15. Top Players of Primary Sclerosing Cholangitis Treatment in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Primary Sclerosing Cholangitis Treatment Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Primary Sclerosing Cholangitis Treatment Players in United States Market, Ranking by Revenue (2021) Table 20. United States Primary Sclerosing Cholangitis Treatment Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Primary Sclerosing Cholangitis Treatment Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Primary Sclerosing Cholangitis Treatment Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Primary Sclerosing Cholangitis Treatment Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Primary Sclerosing Cholangitis Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Primary Sclerosing Cholangitis Treatment Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Primary Sclerosing Cholangitis Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Primary Sclerosing Cholangitis Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Primary Sclerosing Cholangitis Treatment Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Allergan Company Details Table 31. Allergan Business Overview Table 32. Allergan Primary Sclerosing Cholangitis Treatment Product Table 33. Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 34. Allergan Recent Development Table 35. Glenmark Company Details Table 36. Glenmark Business Overview Table 37. Glenmark Primary Sclerosing Cholangitis Treatment Product Table 38. Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 39. Glenmark Recent Development Table 40. Impax Laboratories Company Details Table 41. Impax Laboratories Business Overview Table 42. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product Table 43. Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 44. Impax Laboratories Recent Development Table 45. Mylan Company Details Table 46. Mylan Business Overview Table 47. Mylan Primary Sclerosing Cholangitis Treatment Product Table 48. Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 49. Mylan Recent Development Table 50. Teva Pharmaceuticals Company Details Table 51. Teva Pharmaceuticals Business Overview Table 52. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Table 53. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 54. Teva Pharmaceuticals Recent Development Table 55. Dr. Falk Pharma Company Details Table 56. Dr. Falk Pharma Business Overview Table 57. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product Table 58. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 59. Dr. Falk Pharma Recent Development Table 60. Daewoong Pharmaceutical Company Details Table 61. Daewoong Pharmaceutical Business Overview Table 62. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product Table 63. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 64. Daewoong Pharmaceutical Recent Development Table 65. Epic Pharma Company Details Table 66. Epic Pharma Business Overview Table 67. Epic Pharma Primary Sclerosing Cholangitis Treatment Product Table 68. Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 69. Epic Pharma Recent Development Table 70. Mitsubishi Tanabe Pharma Company Details Table 71. Mitsubishi Tanabe Pharma Business Overview Table 72. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product Table 73. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 74. Mitsubishi Tanabe Pharma Recent Development Table 75. Lannett Company Details Table 76. Lannett Business Overview Table 77. Lannett Primary Sclerosing Cholangitis Treatment Product Table 78. Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 79. Lannett Recent Development Table 80. Bruschettini Company Details Table 81. Bruschettini Business Overview Table 82. Bruschettini Primary Sclerosing Cholangitis Treatment Product Table 83. Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 84. Bruschettini Recent Development Table 85. Shanghai Pharma Company Details Table 86. Shanghai Pharma Business Overview Table 87. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product Table 88. Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 89. Shanghai Pharma Recent Development Table 90. Grindeks Company Details Table 91. Grindeks Business Overview Table 92. Grindeks Primary Sclerosing Cholangitis Treatment Product Table 93. Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 94. Grindeks Recent Development Table 95. Acorda Therapeutics Company Details Table 96. Acorda Therapeutics Business Overview Table 97. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product Table 98. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 99. Acorda Therapeutics Recent Development Table 100. Gilead Sciences Company Details Table 101. Gilead Sciences Business Overview Table 102. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product Table 103. Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 104. Gilead Sciences Recent Development Table 105. Intercept Pharmaceuticals Company Details Table 106. Intercept Pharmaceuticals Business Overview Table 107. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Table 108. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 109. Intercept Pharmaceuticals Recent Development Table 110. Shire Plc Company Details Table 111. Shire Plc Business Overview Table 112. Shire Plc Primary Sclerosing Cholangitis Treatment Product Table 113. Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 114. Shire Plc Recent Development Table 115. NGM Biopharmaceuticals Company Details Table 116. NGM Biopharmaceuticals Business Overview Table 117. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Table 118. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 119. NGM Biopharmaceuticals Recent Development Table 120. Conatus Pharmaceuticals Company Details Table 121. Conatus Pharmaceuticals Business Overview Table 122. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product Table 123. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 124. Conatus Pharmaceuticals Recent Development Table 125. Durect Corporation Company Details Table 126. Durect Corporation Business Overview Table 127. Durect Corporation Primary Sclerosing Cholangitis Treatment Product Table 128. Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 129. Durect Corporation Recent Development Table 130. Sirnaomics Company Details Table 131. Sirnaomics Business Overview Table 132. Sirnaomics Primary Sclerosing Cholangitis Treatment Product Table 133. Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 134. Sirnaomics Recent Development Table 135. Shenzhen HighTide Biopharmaceuticals Company Details Table 136. Shenzhen HighTide Biopharmaceuticals Business Overview Table 137. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product Table 138. Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million) Table 139. Shenzhen HighTide Biopharmaceuticals Recent Development Table 140. Research Programs/Design for This Report Table 141. Key Data Information from Secondary Sources Table 142. Key Data Information from Primary Sources List of Figures Figure 1. Primary Sclerosing Cholangitis Treatment Product Picture Figure 2. Global Primary Sclerosing Cholangitis Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Primary Sclerosing Cholangitis Treatment Market Size 2017-2028 (US$ Million) Figure 4. United States Primary Sclerosing Cholangitis Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Primary Sclerosing Cholangitis Treatment Market Size 2017-2028 (US$ Million) Figure 6. United States Primary Sclerosing Cholangitis Treatment Market Share in Global 2017-2028 Figure 7. Primary Sclerosing Cholangitis Treatment Report Years Considered Figure 8. Product Picture of Liver Transplantation Operation Figure 9. Product Picture of UDCA Drugs Figure 10. Product Picture of PSC Drugs Figure 11. Global Primary Sclerosing Cholangitis Treatment Market Share by Type in 2022 & 2028 Figure 12. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2028) & (US$ Million) Figure 13. Global Primary Sclerosing Cholangitis Treatment Market Share by Type (2017-2028) Figure 14. United States Primary Sclerosing Cholangitis Treatment Market Share by Type in 2022 & 2028 Figure 15. United States Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2028) & (US$ Million) Figure 16. United States Primary Sclerosing Cholangitis Treatment Market Share by Type (2017-2028) Figure 17. Product Picture of Hospital Figure 18. Product Picture of Clinics Figure 19. Product Picture of Other Figure 20. Global Primary Sclerosing Cholangitis Treatment Market Share by Application in 2022 & 2028 Figure 21. Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2028) & (US$ Million) Figure 22. Global Primary Sclerosing Cholangitis Treatment Market Share by Application (2017-2028) Figure 23. United States Primary Sclerosing Cholangitis Treatment Market Share by Application in 2022 & 2028 Figure 24. United States Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2028) & (US$ Million) Figure 25. United States Primary Sclerosing Cholangitis Treatment Market Share by Application (2017-2028) Figure 26. North America Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 27. U.S. Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 28. Canada Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 29. Europe Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 30. Germany Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 31. France Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. U.K. Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. Italy Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. Russia Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 36. China Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 37. Japan Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. South Korea Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. India Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. Australia Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. Taiwan Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Indonesia Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Thailand Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Malaysia Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Philippines Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. Latin America Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 47. Mexico Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 48. Brazil Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Argentina Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size Growth Rate 2017-2028 (US$ Million) Figure 51. Turkey Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 52. Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 53. U.A.E Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 55. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 56. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 57. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 58. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 59. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 60. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 61. Epic Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 62. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 63. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 64. Bruschettini Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 65. Shanghai Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 66. Grindeks Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 67. Acorda Therapeutics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 68. Gilead Sciences Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 69. Intercept Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 70. Shire Plc Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 71. NGM Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 72. Conatus Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 73. Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 74. Sirnaomics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 75. Shenzhen HighTide Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022) Figure 76. Bottom-up and Top-down Approaches for This Report Figure 77. Data Triangulation Figure 78. Key Executives Interviewed

Allergan Glenmark Impax Laboratories Mylan Teva Pharmaceuticals Dr. Falk Pharma Daewoong Pharmaceutical Epic Pharma Mitsubishi Tanabe Pharma Lannett Bruschettini Shanghai Pharma Grindeks Acorda Therapeutics Gilead Sciences Intercept Pharmaceuticals Shire Plc NGM Biopharmaceuticals Conatus Pharmaceuticals Durect Corporation Sirnaomics Shenzhen HighTide Biopharmaceuticals